Recent development of antitumor agents from Chinese herbal medicines; part I. Low molecular compounds

Planta Medica

Volumn 69, Issue 2, 2003, Pages 97-108

  Tang, Weici ^a   Hemm, Ingrid ^a   Bertram, Barbara ^b  

^a Rheinland Pfälzische Technische Universität Kaiserslautern Landau   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Antitumor agents; Chinese herbal medicines; Low molecular natural compounds; Traditional Chinese medicine

Indexed keywords

1,4 BENZOQUINONE DERIVATIVE; ANTINEOPLASTIC AGENT; AURANETIN; BAICALEIN; BENZO[C]PHENANTHRIDINE DERIVATIVE; BERBERINE; BEROLINE; BRUCEANTIN; BRUSATOL; CHELERYTHRINE; DITERPENE; EMBELIN; EPIBERBERINE; FAGARONINE; GROENLANDICINE; HERBACEOUS AGENT; INDIRUBIN; IRISQUINONE A; ISOINDIGO; LYCOBETAINE; NITIDINE; ORIDONIN; PONICIDIN; QUASSINOID DERIVATIVE; RABDOSIA RUBESCENS EXTRACT; SINENSETIN; SKULICAPFLAVONE II; TANGERETIN; UNCLASSIFIED DRUG; WOGONIN;

ALOPECIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANOREXIA; CANCER INHIBITION; CHINESE MEDICINE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DRUG DNA INTERACTION; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; ENZYME INHIBITION; ESOPHAGUS CARCINOMA; HUMAN; HUMAN CELL; HYPERPYREXIA; INDIGO; LEUKEMIA CELL LINE; MOLECULAR WEIGHT; NAUSEA; NONHUMAN; RAT; REVIEW; UTERINE CERVIX CANCER;

ALKALOIDS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DITERPENES; DRUGS, CHINESE HERBAL; FLAVONOIDS; HUMANS; INDOLES; PHYTOTHERAPY; QUASSINS; STRUCTURE-ACTIVITY RELATIONSHIP;

ANIMALIA; INDIGOFERA; RABDOSIA RUBESCENS;

EID: 0037303001     PISSN: 00320943     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-37718     Document Type: Review

References (148)

1. Owen TY, Wang SY, Chang SY, Lu FL, Yang CL, Hsu B. A new antitumor substance - lycobetaine (AT-1840). Ko Hsueh Tung Pao 1976; 21: 285-7
2. He HM, Weng ZY. Structure-activity relationship study of the new anticancer drug lycobetaine (AT-1840). Acta Pharmaceutica Sinica 1989; 24: 302-4
3. Xu B. Pharmacologic study of several anticancer agents of natural origin. Proceedings of Intern Summit on Drugs from Natural Products. October 9 - 12, 1995 Beijing, China: Vol 1
4. Ghosal S, Singh SK, Kumar Y, Unnikrishnan S, Chattopadhyay S. Chemical constituents of Amaryllidaceae. XXVI. The role of ungeremine in the growth-inhibiting and cytotoxic effects of lycorine: evidence and speculation. Planta Medica 1988; 54: 114-6
5. Wang XW, Yu WJ, Shen ZM, Yang JL, Xu B. Cytotoxicity of hydroxycamptothecin and four other antineoplastic agents on KB cells. Acta Pharmacologica Sinica 1987; 8: 86-90
6. Wu YL, Wu YX, Yu CS, Zhang SY, Su ZC, Jiang SJ. The cytocidal effect of AT-1840 and parvovirus H-1 on gastric cancer cells. Shanghai Medical Journal 1988; 11: 683-8
7. Liu J, Yang SL, Xu B. Characteristics of the interaction of lycobetaine with DNA. Acta Pharmacologica Sinica 1989; 10: 437-42
8. Liu J, Yang SL, Xu B. Effects of lycobetaine on chromatin structure and activity of murine hepatoma cells. Science in China Series B 1990; 33: 1459-65
9. Chen JZ, Chen KX, Jiang HL, Lin MW, Ji RY. Theoretical investigation on interaction binding of analogs of AT-1840 to double-stranded polynucleotide. Progress in Natural Science 1997; 7: 329-35
10. Wang P, Shi GB, Song GQ, Chen KX, Ji RY. Assignment of proton resonances and conformational characterization of oligodeoxyribonucleic acid d(CCGTACGG) in solution. Acta Biochimica and Biophysica Sinica 1996; 28: 703-5
11. Gan L, Liu XJ, Chen KL, Ji YY. Computer simulation on the interaction between antitumor agent lycobetaine and DNA. Gaojishu Tongxun 1992; 2: 30-3
12. Barthelems HU, Niederberger E, Roth T, Schulte K, Tang WC, Zankl H, Fiebig HH, Eisenbrand G, Marko D. Lycobetaine acts as a selective topoisomerase IIβ poison and inhibits the growth of human tumor cells. British Journal of Cancer 2001; 85: 1585-91
13. Zhang SY, Lu FL, Yang JL, Wang LJ, Xu B. Effect on animal tumors and toxicity of lycobetaine acetate. Acta Pharmacologica Sinica 1981; 2: 41-5
14. Hua DH, Saha S, Takemoto DJ. Anticancer activities of 2,5,8,9-substituted 6-oxo-1,2,3,4,5,6-hexahydrophenanthridines on multi-drug-resistant phenotype cells. Anticancer Research 1997; 17A: 2435-41
15. Niederberger E. Mechanismus-orientierte Untersuchungen zur anti-neoplastischen Wirkung von Naturstoffen und Naturstoff-Derivaten. Thesis, Universtiy of Kaiserslautern, Germany: 1998
16. Schulte K. Synthese von Phenanthridin- und Benzo[c]phenanthridin-Derivaten und Untersuchungen auf ihre biologische Wirkung. Thesis, Universtiy of Kaiserslautern, Germany: 2000
17. Kushida N, Atsumi S, Koyano T, Umezawa K. Induction of flat morphology in K-ras-transformed fibroblasts by lycorine, an alkaloid isolated from the tropical plant Eucharis grandiflora. Drugs under Experimental and Clinical Research 1997; 23: 151-5
18. Fang SD, Wang LK, Hecht SM. Inhibitors of DNA topoisomerase 1 isolated from the roots of Zanthoxylum nitidum. Journal of Organic Chemistry 1993; 58: 5025-7
19. The Pharmacopoeia of the People's Republic of China.; Vol I Ed 2000 Chemical Industrial Press, Beijing, PR China
20. Colombo ML, Bosisio E. Pharmacological activities of Chelidonium majus L. (Papaveraceae). Pharmacological Research 1996; 33: 127-34
21. Stermitz FR, Gillespie JP, Amoros LG, Romero R, Stermitz TA, Larson KA, Earl S, Ogg JE. Synthesis and biological activity of some antitumor benzophenanthridinium salts. Journal of Medicinal Chemistry 1975; 18: 708-13
22. Fan YJ, Zhou J, Li M. Effect of nitidine chloride on the life cycle of Ehrlich ascites carcinoma cells in mice. Acta Pharmacologica Sinica 1981; 2: 46-9
23. Wang MH. Isolation of antitumor alkaloids from Zanthoxylum nitidum and structural study of its alkaloid C. Chinese Pharmaceutical Bulletin 1981; 16: 48
24. Zhu DY. Recent advances on the active components in Chinese medicines. Abstracts of Chinese Medicines (Hong Kong) 1987; 1: 251-286
25. Kubova N, Smekal E, Kleinwachter V, Cushman M. Binding properties of nitidine and its indenoisoquinoline analog with DNA. Studia Biophysica 1986; 114: 251-6
26. Gatto B, Sanders MM, Yu C, Wu HY, Makhey D, LaVoie EJ, Liu LF. Identification of topoisomerase 1 as the cytotoxic target of the protoberberine alkaloid coralyne. Cancer Research 1996; 56: 2795-800
27. Del Poeta M, Chen SF, Von Hoff D, Dykstra CC, Wani MC, Manikumar G, Heitman J, Wall ME, Perfect JR. Comparison of in vitro activities of camptothecin and nitidine derivatives against fungal and cancer cells. Antimicrobial Agents and Chemotherapy 1999; 43: 2862-78
28. Wang X, Henningfeld KA, Hecht SM. DNA topoisomerase 1-mediated formation of structurally modified DNA duplexes. Effects of metal ions and topoisomerase 1 inhibitors. Biochemistry 1998; 37: 2691-700
29. Chen YZ, Tang GY, Xu BJ, Wu QJ, Lu CZ, Li JQ, Huang ZX. The formation and crystal structure of dihydronitidine and discussion of anticancer mechanism of nitidine cation. Science in China Series B 1992; 35: 1101-9
30. Larsen AK, Grondard L, Couprie J, Desoize B, Comoe L, Jardillier JC, Riou JF. The antileukemic alkaloid fagaronine is an inhibitor of DNA topoisomerases 1 and 11. Biochemical Pharmacology 1993; 46: 1403-12
31. Fleury F, Sukhanova A, Ianoul A, Devy J, Kudelina I, Duval O, Alix AJ, Jardillier JC, Nabiev I. Molecular determinants of site-specific inhibition of human DNA topoisomerase 1 by fagaronine and ethoxidine. Relation to DNA binding. Journal of Biological Chemistry 2000; 275: 3501-9
32. Pezzuto JM, Antosiak SK, Messmer WM, Slaytor MB, Honig GR. Interaction of the antileukemic alkaloid, 2-hydroxy-3,8,9-trimethoxy-5-methylbenzo[c]phenanthridine (fagaronine), with nucleic acids. Chemico-Biological Interactions 1983; 43: 323-39
33. Herbert JM, Augereau JM, Gleye J, Maffrand JP. Chelerythrine is a potent and specific inhibitor of protein kinase C. Biochemical and Biophysical Research Communications 1990; 172: 993-9
34. 2+/calmodulin mediated pathways regulate the uptake of 1-DOPA in mouse neuroblastoma neuro 2A cells. Life Sciences 2000; 67: 3209-20
35. Fernandez Y, Ramakrishnan R, Rathinavelu A. GI-101A breast tumor cell growth. Life Sciences 2000; 67: 567-75
36. Ramakrishnan R, Zell JA, Malave A, Rathinavelu A. Expression of vascular endothelial growth factor mRNA in GI-101A and HL-60 cell lines. Biochemical and Biophysical Research Communications 2000; 270: 709-13
37. Mueller H, Liu R, David F, Eppenberger U. Selective modulation of protein kinase A and protein kinase C activities in epidermal growth factor (EGF)-stimulated MCF-7 breast cancer cells. Biological Chemistry 1997; 378: 1023-9
38. Lamm ML, Long DD, Goodwin SM, Lee C. Transforming growth factor-β1 inhibits membrane association of protein kinase Cα in a human prostate cancer cell line, PC3. Endocrinology 1997; 138: 4657-64
39. Zhu GH, Wong BC, Eggo MC, Yuen ST, Lai KC, Lam SK. Pharmacological inhibition of protein kinase C activity could induce apoptosis in gastric cancer cells by differential regulation of apoptosis-related genes. Digestive Diseases and Sciences 1999; 44: 2020-6
40. Chmura SJ, Dolan ME, Cha A, Mauceri HJ, Kufe DW, Weichselbaum RR. In vitro and in vivo activity of protein kinase C inhibitor chelerythrine chloride induces tumor cell toxicity and growth delay in vivo. Clinical Cancer Research 2000; 6: 737-42
41. Wolff J, Knipling L. Antimicrotubule properties of benzophenanthridine alkaloids. Biochemistry 1993; 32: 13334-9
42. Wang BH, Lu ZX, Polya GM. Inhibition of eukaryote protein kinases by isoquinoline and oxazine alkaloids. Planta Medica 1997; 63: 494-8
43. Vavreckova C, Gawlik I, Muller K. Benzophenanthridine alkaloids of Chelidonium majus. II. Potent inhibitory action against the growth of human keratinocytes. Planta Medica 1996; 62: 491-4
44. Ahmad N, Gupta S, Husain MM, Heiskanen KM, Mukhtar H. Differential antiproliferative and apoptotic response of sanguinarine for cancer cells versus normal cells. Clinical Cancer Research 2000; 6: 1524-8
45. Dai JR, Chai H, Pezzuto JM, Kinghorn AD, Tsauri S, Padmawinata K. Studies on Indonesian Plants. V. Cytotoxic constituents of the roots of the Indonesian medicinal plant Fibraurea chloroleuca. Phytotherapy Research 1993; 7: 290-4
46. Chen KT, Hao DM, Liu ZX, Chen YC, You ZS. Effect of berberine alone or in combination with argon ion laser treatment on the 9L rat glioma cell line. Chinese Medicinal Journal (Engl) 1994; 107: 808-12
47. Iizuka N, Miyamoto K, Okita K, Tangoku A, Hayashi H, Yosino S, Abe T, Morioka T, Hazama S, Oka M. Inhibitory effect of Coptidis Rhizoma and berberine on the proliferation of human esophageal cancer cell lines. Cancer Letters 2000; 148: 19-25
48. Chi CW, Chang YF, Chao TW, Chiang SH, Peng FK, Lui WY, Liu TY. Flow-cytometric analysis of the effect of berberine on the expression of glucocorticoid receptors in human hepatoma HepG2 cells. Life Sciences 1994; 54: 2099-2107
49. Lin HL, Chang YF, Liu TY, Wu CW, Chi CW. Submicromolar paclitaxel induces apoptosis in human gastric cancer cells at early G1 phase. Anticancer Research 1998; 18: 3443-9
50. Yang IW, Chou CC, Yung BY. Dose-dependent effects of berberine on cell cycle pause and apoptosis in Balb/c 3T3 cells. Naunyn-Schmiedebergs Archives of Pharmacology 1996; 354: 102-8
51. Chang KS, Gao C, Wang LC. Berberine-induced morphologic differentiation and down-regulation of c-Ki-ras2 protooncogene expression in human teratocarcinoma cells. Cancer Letters 1990; 55: 103-8
52. Miura N, Yamamoto M, Ueki T, Kitani T, Fukuda K, Komatsu Y. Inhibition of thymocyte apoptosis by berberine. Biochemical Pharmacology 1997; 53: 1315-22
53. Kuo CL, Chou CC, Yung BY. Berberine complexes with DNA in the berberine-induced apoptosis in human leukemic HL-60 cells. Cancer Letters 1995; 93: 193-200
54. Ren J, Chaires JB. Sequence and structural selectivity of nucleic acid binding ligands. Biochemistry 1999; 38: 16067-75
55. Lee SJ, Kim JB, Lee SW, Kim JH. Enhanced cytotoxicity of berberine and some anticancer nucleotides against tumor cell-lines. Archives of Pharmacal Research 1995; 18: 138-9
56. Zhang RX, Dougherty DV, Rosenblum ML. Laboratory studies of berberine used alone and in combination with 1,3-bis(2-chloroethyl)-1-nitrosourea to treat malignant brain tumors. Chinese Medicinal Journal (English Edition) 1990; 103: 658-65
57. Lin HL, Liu TY, Wu CW, Chi CW. Berberine modulates expression of mdr1 gene product and the responses of digestive track cancer cells to Paclitaxel. British Journal of Cancer 1999; 81: 416-22
58. Lin HL, Liu TY, Lui WY, Chi CW. Up-regulation of multidrug resistance transporter expression by berberine in human and murine hepatoma cells. Cancer 1999; 85: 1937-42
59. Dai JR, Chai H, Pezzuto JM, Kinghorn AD, Tsauri S, Padmawinata K. Studies on Indonesian Plants. V. Cytotoxic constituents of the roots of the Indonesian medicinal plant Fibraurea chloroleuca. Phytotherapy Research 1993; 7: 290-4
60. Makhey D, Gatto B, Yu C, Liu A, Liu LF, LaVoie EJ. Protoberberine alkaloids and related compounds as dual inhibitors of mammalian topoisomerase I and II. Medicinal Chemistry Research 1995; 5: 1-12
61. Kobayashi Y, Yamashita Y, Fuji N, Takaboshi K, Kawakami T, Kawamura M, Mizukami T, Nakano H. Inhibitors of DNA topoisomerase I and II isolated from the Coptis rhizomes. Planta Medica 1995; 61: 414-8
62. Kim SA, Kwon Y, Kim JH, Muller MT, Chung IK. Induction of topoisomerase II-mediated DNA cleavage by a protoberberine alkaloid, berberrubine. Biochemistry 1998; 37: 16316-24
63. Xia GC, Zang JY, Lu XM, Xiao PG. Resource utilization and herbal study of "malinzi" (Iris lactea Pall. var. chinensis). Acta Pharmacentica Sinica 1985: 20: 316-9
64. Li DH, Hao XG, Zhang SK, Wang SX, Liu RY, Ma KS, Yu SP, Jiang H, Guan JF. Antitumor effect and toxicity of irisquinone. Acta Pharmacologica Sinica 1981; 2: 131-4
65. 14 tumor. Chinese Journal of Clinical Oncology 1986; 13: 241-3
66. Li WM, Wang SH, Kuang P, Qu BX, Song HL, Zhu LX. Radiosensitizing effect of an active principle 1q7611 from the seed of Iris lactea var. chinenesis. Tumor 1987; 7: 97-9
67. Chitra M, Sukumar E, Suja V, Devi CS. Antitumor, anti-inflammatory and analgesic property of embelin, a plant product. Chemotherapy 1994; 40: 109-113
68. 3H]-Thymidine uptake and lipid peroxidation by tumor cells on embelin treatment: an in vitro study. Oncology 1995; 52: 66-8
69. Yuan K, Hu R, Ji C, Yin M. New method for preparing oridonin by column chromatography. China Journal of Chinese Materia Medica 1997; 22: 478-80, 511
70. Wang RL, Gao BL, Xiong ML, Mei QD, Fan KS, Zuo ZK, Lang TL, Gao GQ, Ji ZC, Wei DC. Potentiation by Rabdosia rubescens on chemotherapy of advanced esophageal carcinoma. Chinese Journal of Oncology 1986; 8: 297-9
71. Wang RL. A report of 40 cases of esophageal carcinoma surviving for more than 5 years after treatment with drugs. Chinese Journal of Oncology 1993; 15: 300-2
72. Porterfield H. UsToo PC-SPES surveys: review of studies and update of previous survey results. Molecular Urology 2000; 4: 289-91
73. de la Taille A, Hayek OR, Burchardt M, Burchardt T, Katz AE. Role of herbal compounds (PC-SPES) in hormone-refractory prostate cancer: two case reports. Journal of Alternative and Complementary Medicine 2000; 6: 449-51
74. Lou FC, Ding LS, Ma QY, Du FL. Natural antineoplastic compounds and their structure-activity relationships. Journal of Nanjing College of Pharmacy 1986; 17: 152-9
75. Fujita T, Takeda Y, Sun HD, Minami Y, Marunaka T, Takeda S, Yamada Y, Togo T. Cytotoxic and antitumor activities of Rabdosia diterpenoids. Planta Medica 1988; 54: 414-7
76. Wang MY, Lin C, Zhang TM. Cytokinetic effects of oridonin on leukemia L1210 cells. Acta Pharmacologica Sinica 1985; 6: 195-8
77. Li XT, Lin C, Li PY. Comparison of in vitro assays for the cytotoxic effect of anticancer drugs. Chinese Journal of Oncology 1986; 8: 184-6
78. Yu JJ, Reed E. Preliminary study of the effect of selected Chinese natural drugs on human ovarian cancer cells. Oncology Reporter 1995; 2: 571-5
79. Wang MY, Lin C, Zhang TM. Autoradiographic study on the effects of oridonin on DNA, RNA and protein synthesis of leukemia L 1210 cells. Acta Pharmacologica Sinica 1987; 8: 164-5
80. Li Y, Zhang TM. Effect of oridonin on cell-free DNA synthesis in vitro. Acta Pharmacologica Sinica 1988; 9: 465-7
81. Gao ZG, Ye QX, Zhang TM. Synergistic effect of oridonin and cisplatin on cytotoxicity and DNA cross-link against mouse sarcoma S180 cells in culture. Acta Pharmacologica Sinica 1993; 14: 561-4
82. 5 and nitrocaphane. Acta Pharmacologica Sinica 1986; 7: 457-60
83. Jiang B, Lu ZQ, Hou AJ, Zhao QS, Sun HD. ent-Kaurane diterpenoids from Isodon lungshengensis. Journal of Natural Products 1999; 62: 941-5
84. Sun HD, Lin ZW, Niu FD, Lin LZ, Chai HB, Pezzuto JM, Cordell GA. Cytotoxic ent-kaurene diterpenoids from three Isodon species. Phytochemistry 1995; 38: 437-42
85. Fujita E, Nagao y, Node M, Kaneko K, Nakazawa S, Kuroda H. Antitumor activity of the Isodon diterpenoids: structural requirements for the activity. Experientia 1976; 32: 203-6
86. Zhai JK, Han WC, Ju XH. Crystal structure of nervosin and the electronic structure of its anticancer-active zone. Acta Chimica Sinica 1993; 51: 854-9
87. Fujita E, Nagao Y, Kaneko K, Nakazawa S, Kuroda H. The antitumor and antibacterial activity of the Isodon diterpenoids. Chemical and Pharmaceutical Bulletin (Tokyo) 1976; 24: 2118-27
88. Hall IH, Lee KH, Okano M, Sims D, Ibuka T, Liou YF, Imakura Y. Antitumor agents. XLII. Comparison of antileukemic activity of helenalin, brusatol and bruceantin and their esters on different strains of P388 lymphocytic leukemic cells. Journal of Pharmaceutical Sciences 1981; 70: 1147-50
89. Liao LL, Kupchan SM, Horwith SB. Mode of action of the antitumor compound bruceantin, an inhibitor of protein synthesis. Molecular Pharmacology 1976; 12: 167-76
90. Garnick MB, Blum RH, Canellos GP, Mayer RJ, Parker L, Skarin AT, Li FP, Henderson IC, Frei E. Phase I trial of bruceantin. Cancer Treatment Reports 1979; 63: 1929-32
91. Amato DA, Borden EC, Shiraki M, Enterline HAT, Rosenbaum C, Davis HL, Paul AR, Stevens CM, Lerner HJ. Evaluation of bleomycin, chlorozotocin, MGBG, and bruceantin in patients with advanced soft tissue sarcoma, bone sarcoma, or mesothelioma. Investigational New Drugs 1985; 3: 397-401
92. Wiseman CL, Yap HY, Bedikian AY, Bodey GP, Blumenschein GR. Phase II trial of bruceantin in metastatic breast carcinoma. American Journal of Clinical Oncology 1982; 5: 389-91
93. Cheng JH, Long H, Zu JL. Therapeutic analysis of treatment of recurrent metastatic gastrointestinal carcinomas in 35 patients with Brucea javanica emulsion "Yandanziyou". Chinese Traditional Patent Medicine 1991; 13: 21-2
94. Wang ZQ. Combined therapy of brain metastasis in lung cancer. Chinese Journal of Integrated Traditional and Western Medicine 1992; 12: 609-10
95. Lu JB, Shu SY, Cai JQ. Experimental study on effect of Brucea javanica oil emulsion on rabbit intracranial pressure. Chinese Journal of Integrated Traditional and Western Medicine 1994; 14: 610-11
96. Wang JZ, Chen DY, Su YY. Analytical study on processing of Scutellaria baicalensis Georgi by HPLC. China Journal of Chinese Materia Medica 1994; 19: 340-1
97. Tomimori T, Miyaichi Y, Kizu H. On the flavonoid constituents from the roots of Scutellaria baicalensis Georgi. I. Yakugaku Zasshi 1982; 102: 388-91
98. Motoo Y, Sawabu N. Antitumor effects of saikosaponins, baicalin and baicalein on human hepatoma cell lines. Cancer Letters 1994; 86: 91-5
99. Ikemoto S, Sugimura K, Yoshida N, Yasumoto R, Wada S, Yamamoto K, Kishimoto T. Antitumor effects of scutellariae radix and its components baicalein, baicalin, and wogonin on bladder cancer cell lines. Urology 2000; 55: 951-5
100. Niederberger E, Meiers S, Genzlinger A, Zankl H, Tang WC, Eisenbrand G, Marko D. Flavones and inhibition of tumor cell growth: new aspects on the mechanism of action. In: Eisenbrand G, Dayan AD, Elias PS, Grunow W, Schlatter J, editors. Carcinogenic and anticarcinogenic factors in food Wiley-VCH, Weinheim: 1998: 512-3
101. Matsuzaki Y, Kurokawa N, Terai S, Matsumura Y, Kobayashi N, Okita K. Cell death induced by baicalein in human hepatocellular carcinoma cell lines. Japanese Journal of Cancer Research 1996; 87: 170-7
102. Austin CA, Patel S, Ono K, Nakane H, Fisher LM. Site-specific DNA cleavage by mammalian DNA topoisomerase 11 induced by novel flavone and catechin derivatives. Biochemical Journal 1992; 282: 883-9
103. Chan FL, Choi HL, Chen ZY, Chan PS, Huang Y. Induction of apoptosis in prostate cancer cell lines by a fiavonoid, baicalin. Cancer Letters 2000; 160: 219-28
104. Huang HC, Hsieh LM, Chen HW, Lin YS, Chen JS. Effects of baicalein and esculetin on transduction signals and growth factors expression in T-lymphoid leukemia cells. European Journal of Pharmacology 1994; 268: 73-8
105. So FV, Guthrie N, Chambers AF, Moussa M, Carroll KK. Inhibition of human breast cancer cell proliferation and delay of mammary tumorigenesis by flavonoids and Citrus juices. Nutrition and Cancer 1996; 26: 167-81
106. So FV, Guthrie N, Chambers AF, Carroll KK. Inhibition of proliferation of estrogen receptor-positive MCF-7 human breast cancer cells by flavonoids in the presence and absence of excess estrogen. Cancer Letters 1997; 112: 127-33
107. Chang WS, Lee YJ, Lu FJ, Chiang HC. Inhibitory effects of flavonoids on xanthine oxidase. Anticancer Research 1993; 13: 2165-70
108. Umezawa K. Inhibition of experimental metastasis by enzyme inhibitors from microorganisms and plants. Advances in Enzyme Regulation 1996; 36: 267-81
109. Kawaii S, Tomono Y, Katase E, Ogawa K, Yano M. Antiproliferative activity of flavonoids on several cancer cell lines. Bioscience, Biotechnology and Biochemistry 1999; 63: 896-9
110. Kawaii S, Tomono Y, Katase E, Ogawa K, Yano M. Effect of Citrus flavonoids on HL-60 cell differentiation. Anticancer Research 1999; 19(A): 1261-9
111. Kawaii S, Tomono Y, Katase E, Ogawa K, Yano M. HL-60 differentiating activity and flavonoid content of the readily extractable fraction prepared from Citrus juices. Journal of Agricultural and Food Chemistry 1999; 47: 128-35
112. Bracke M, Vyncke B, Opdenakker G, Foidart JM, De Pestel G, Mareel M. Effect of catechins and citrus flavonoids on invasion in vitro. Clinical and Experimental Metastasis 1991; 9: 13-25
113. Takanaga H, Ohnishi A, Yamada S, Matsuo H, Morimoto S, Shoyama Y, Ohtani H, Sawada Y. Polymethoxylated flavones in orange juice are inhibitors of P-glycoprotein but not cytochrome P450 3A4. Journal of Pharmacology and Experimental Therapeutics 2000; 293: 230-6
114. Ikegawa T, Ushigome F, Koyabu N, Morimoto S, Shoyama Y, Naito M, Tsuruo T, Ohtani H, Sawada Y. Inhibition of P-glycoprotein by orange juice components, polymethoxyflavones in adriamycin-resistant human myelogenous leukemia (K562/ADM) cells. Cancer Letters 2000; 160: 21-8
115. Institute of Haematology, Chinese Academy of Medical Sciences. Clinical studies of Dang Gui Lu Hui Wan in the treatment of CML. Chinese Journal of Internal Medicine 1979; 15: 86-8
116. Wu LM, Yang YP, Zhu ZH. Studies on the active principles of Indigofera tinctoriain the treatment of CML. Comm Chinese Herb Med 1979; 9: 6-8
117. Ji XJ, Zhang FR, Lei JL, Xu YT. Studies on the antineoplastic effect and toxicity of synthetic indirubin. Acta Pharmacentica Sinica 1981; 16: 146-8
118. Indirubin cooperative group. Clinical study of indirubin in the treatment of 314 patients with chronic granulocytic leukemia. Chinese Journal of Hematology 1980; 1: 132
119. Gan WJ, Yang TY, Wen SD, Liu YY, Tan Z, Deng CA, Wu JX, Liu MP. Studies on the mechanism of indirubin action in treatment of chronic myelocytic leukemia (CML). II. 5′-Nucleotidase in the peripheral white blood cells of CML. Chinese Journal of Hematology 1985; 6: 611-3
120. Qian LS, Xue YP, Zhang XM, Yang TY, Yan WW, Wang ZC. Observation on the long-period effect of indirubin in the treatment of 57 cases of chronic myelogenous leukemia. Chinese Journal of Hematology 1991; 12: 125-7
121. Zhang L, Wu GY, Qiu CC. Effect of indirubin on DNA synthesis in vitro. Acta Academiae Medicinae Sinicae 1985; 7: 112-6
122. Gan WJ, Yang TY, Wang ZC, Qian LS, Ma J, Ge YQ, Cheng BJ, Li ZM, Bo HQ. Studies on the antitumor mechanism of indirubin by treatment of chronic myelocytic leukemia (CML). Chinese Biochemical Journal 1987; 3: 225-30
123. Du DJ, Ceng QT. Effect of indirubin on the incorporation of isotope labeled precursors into nucleic acid and protein of tumor tissues. Chinese Traditional and Herbal Drugs 1981; 12: 406-9
124. 3H-TdR into DNA of liver and spleen of L7212, a lymphatic leukemia in mice. Chinese Journal of Hematology 1982; 3: 277-80
125. Wu GY, Liu JZ, Fang FD, Zuo J. Studies on the mechanism of indirubin action in the treatment of chronic granulocytic leukemia. V. Binding between indirubin and DNA and identification of the type of binding. Scientia Sinica 1982; 25B: 1071-9
126. Lee K, Shih CY, Yang TY, Chen LS, Chao WM, Sun CS, Wang TC, Pien SK, Sing KH. Ultratherapeutic effect of indirubin for human chronic granulocytic leukemia. National Medical Journal of China 1979; 59: 129-32
127. 3H-TdR. Chinese Journal of Oncology 1987; 9: 418-20
128. Chen KY, Wang ZF, Li CY, Li WX. Study on indirubin and indigo by ESR spectrometry. Chemical Journal of Chinese Universities 1989; 10: 869-71
129. Hoessel R, Leclerc S, Endicott JA, Nobel ME, Lawrie A, Tunnah P, Leost M, Damiens E, Marie D, Marko D, Niederberger E, Tang W, Eisenbrand G, Meijer L. Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nature Cell Biology 1999; 1: 60-7
130. 1) by indirubin derivatives in human tumour cells. British Journal of Cancer 2001; 84: 283-9
131. 5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors? Journal of Biological Chemistry 2001; 276: 251-60
132. Sielecki TM, Boylan JF, Benfield PA, Trainor GL. Cyclin-dependent kinase inhibitors: useful targets in cell cycle regulation. Journal of Medicinal Chemistry 2000; 43: 1-18
133. Buolamwini JK. Cell cycle molecular targets in novel anticancer drug discovery. Current Pharmaceutical Design 2000; 6: 379-92
134. Wang JH, You YC, Mi JX, Ying HG. Effect of indirubin on hematopoietic cell production. Acta Pharmacologica Sinica 1981; 2: 241-4
135. Wen ZJ, Liu Y, Yi ZP, Yang YS. Effects of indirubin on the histology and histochemistry of canine and rat livers. Bulletin of Chinese Materia Medica 1988; 13: 306-7
136. Sichnan Institute of Traditional Chinese Medicine. Subacute toxicity of indirubin in dogs. Chinese Traditional and Herbal Drugs 1981; 12: 27-9
137. Cai YY, Xu CL, Li SH, Liu Y. Studies on sister chromatid exchanges induced by harringtonine, indirubin and pyquiton before or after activation with microsome enzyme. Acta Academiae Medicinae Sinicae 1983; 5: 161-4
138. Feng BZ, Zhang YH, Qian LS, Chu YL. Effect of indirubin on SCE frequencies of BM cells in chronic myeloid leukemia. Acta Academiae Medicinae Sinicae 1984; 6: 308-10
139. Feng BZ. Sister chromatid exchange frequency of bone marrow cells and its response to indirubin in chronic myeloid leukemia. Chinese Journal of Oncology 1984; 6: 357-60
140. 1-substituted derivatives of indirubin, an antileukemic compound. Acta Pharmacentica Sinica 1984; 19: 513-8
141. Ji XJ Zhang FR. Antineoplastic effect of indirubin derivatives and their structure-activity relationship. Acta Pharmacentica Sinica 1985; 20: 137-9
142. Zeng QT, Du DJ, Xie DC, Wang XP, Rau CQ. Antitumor activities of indirubin derivatives. Chinese Traditional and Herbal Drugs 1982; 13: 24-30
143. Gu YC, Li GL, Yang YP, Fu JP, Li CZ. Synthesis of some halogenated indirubin derivatives. Acta Pharmacentica Sinica 1989; 24: 629-32
144. Zeng QT, Du DJ, Si XF, Ran CQ, Wu XP. Antitumor activity of 5′-iodoin-dirubin. West China Pharm Sci 1991; 6: 63-8
145. Wu GY, Liu JZ, Zhang L. Effect of bisindole compounds with three different kinds of linkage on the synthesis of nucleic acid and protein. Progress in Biochemistry and Biophysics 1985; 61: 48-51
146. Wu KM, Zhang MY, Fang Z, Huang L. Potential antileukemic agents, synthesis of derivatives of indirubin, indigo, and isoindigotin. Acta Pharmacentica Sinica 1985; 20: 821-6
147. Ji XJ, Liu XM, Li K, Chen RH, Wang LG. Pharmacological studies of meisoindigo: absorption and mechanism of action. Biomedical and Environmental Sciences 1991; 4: 332-7
148. Liu XM, Wang LG, Li HY, Ji XJ. Induction of differentiation and down-regulation of c-myb gene expression in ML-1 human myeloblastic leukemia cells by the clinically effective anti-leukemia agent meisoindigo. Biochemical Pharmacology 1996; 51: 1545-51